Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NextCure Inc (NXTC)
NASDAQ:NXTC
NextCure (NXTC) Stock Price & Analysis
281 Followers
NXTC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.98 - $2.57
Previous Close$1.69
Volume48.83K
Average Volume (3M)96.39K
Market Cap
$47.27M
Enterprise Value-$64.81M
Total Cash (Recent Filing)$118.21M
Total Debt (Recent Filing)$6.12M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 01, 2024EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.29
Shares Outstanding27,973,289
10 Day Avg. Volume81,771
30 Day Avg. Volume96,392
Standard Deviation0.24
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.36
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.03
Forecast
1Y Price Target
$5.00Price Target Upside195.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
NextCure News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsBoth had >70% tumor reduction, which is quite a deep level of response, and one patient has surpassed 12 months on treatment and is still ongoing, while the other patient is approaching 8 months on treatment and is still ongoing, which we view as durable responses.
Financial PerformanceNextcure ended 1Q:24 with $96M in cash and reiterated runway guidance into 2H:26.
Preclinical DataLNCB74 demonstrates anti-tumor activity in multiple tumor types.
Bears Say
Financial PerformanceThe PFS for the initial 19 patients was noted to be 8.1 months, which was found to be very encouraging.
Product DevelopmentThe new update did not include any additional responses, leading to a total ORR of 5.4%.
Strategic FocusThe company has deprioritized development for NC525 in AML, reflecting a strategic shift in focus.
---
Ownership Overview
50.08%
Insiders
7.47% Mutual Funds
3.77% Other Institutional Investors
38.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $0.98 and its highest was $2.57 in the past 12 months.
What is NextCure Inc’s market cap?
Currently, no data Available
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on May 02, 2024. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.46 by -$0.15.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -$0.38.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 27,973,290 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.46. Following the earnings report the stock price went up 2.685%.
Which hedge fund is a major shareholder of NextCure Inc?
Among the largest hedge funds holding NextCure Inc’s share is Harbourvest Partners Llc. It holds NextCure Inc’s shares valued at 22K.
---
NextCure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (195.86% Upside)
$5.00 (195.86% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 11.3%
Last 30 Days ▼ 11.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.97%
12-Months-Change
Fundamentals
Return on Equity
-50.33%
Trailing 12-Months
Asset Growth
-31.37%
Trailing 12-Months
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.
---
NXTC Stock 12 Month Forecast
Average Price Target
$5.00
▲(195.86% Upside)
Technical Analysis
MacroGenics
―
Crispr Therapeutics AG
―
Arvinas Holding Company
―
Allogene Therapeutics
―
Best Analysts Covering NXTC
1 Year
---